Compare Stocks → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BCTXWNASDAQ:BIOTWNASDAQ:LBPSWNASDAQ:LIXTW Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCTXWBriaCell Therapeutics$0.94$1.34$0.71▼$3.30N/AN/A24,126 shs111,068 shsBIOTWBiotech Acquisition$0.01-90.3%$0.04$0.00▼$0.48N/AN/A71,688 shs414,400 shsLBPSW4D pharma$0.00$0.04▼$1.29N/AN/A20,931 shsN/ALIXTWLixte Biotechnology$0.05$0.07$0.03▼$0.14N/AN/A4,700 shsN/A10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCTXWBriaCell Therapeutics+4.66%-0.84%-21.51%-47.38%-68.50%BIOTWBiotech Acquisition0.00%0.00%0.00%0.00%0.00%LBPSW4D pharma0.00%0.00%0.00%0.00%+4,811.11%LIXTWLixte Biotechnology0.00%0.00%+3.91%-28.59%-22.75%Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCTXWBriaCell TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ABIOTWBiotech AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ALBPSW4D pharmaN/AN/AN/AN/AN/AN/AN/AN/ALIXTWLixte BiotechnologyN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCTXWBriaCell TherapeuticsN/AN/AN/AN/ABIOTWBiotech AcquisitionN/AN/AN/AN/ALBPSW4D pharmaN/AN/AN/AN/ALIXTWLixte BiotechnologyN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCTXWBriaCell TherapeuticsN/AN/AN/AN/AN/AN/ABIOTWBiotech AcquisitionN/AN/AN/AN/AN/AN/ALBPSW4D pharma$522KN/AN/AN/AN/AN/ALIXTWLixte BiotechnologyN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCTXWBriaCell TherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/ABIOTWBiotech AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/ALBPSW4D pharmaN/AN/A0.00N/AN/AN/AN/AN/AN/ALIXTWLixte BiotechnologyN/AN/A0.00∞N/AN/AN/AN/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCTXWBriaCell TherapeuticsN/AN/AN/AN/AN/ABIOTWBiotech AcquisitionN/AN/AN/AN/AN/ALBPSW4D pharmaN/AN/AN/AN/AN/ALIXTWLixte BiotechnologyN/AN/AN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCTXWBriaCell TherapeuticsN/ABIOTWBiotech AcquisitionN/ALBPSW4D pharmaN/ALIXTWLixte BiotechnologyN/AInsider OwnershipCompanyInsider OwnershipBCTXWBriaCell TherapeuticsN/ABIOTWBiotech AcquisitionN/ALBPSW4D pharmaN/ALIXTWLixte BiotechnologyN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBCTXWBriaCell Therapeutics16N/AN/ANot OptionableBIOTWBiotech AcquisitionN/AN/AN/ANot OptionableLBPSW4D pharmaN/AN/AN/ANot OptionableLIXTWLixte Biotechnology3N/AN/ANot OptionableLIXTW, LBPSW, BIOTW, and BCTXW HeadlinesSourceHeadlineNEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIESfinance.yahoo.com - March 27 at 8:44 AMProfessor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Researchfinance.yahoo.com - February 27 at 9:47 AMLixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCIfinanznachrichten.de - February 26 at 12:39 PMLixte CEO Takes On a New Courselabusinessjournal.com - February 5 at 8:58 AMLixte Biotechnology Holdings Inc (LIXT)uk.investing.com - February 1 at 12:55 PMLIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovachfinance.yahoo.com - October 9 at 9:39 AMLixte Biotechnology Holdings, Inc.: LIXTE Appoints Bas van der Baan as President and Chief Executive Officerfinanznachrichten.de - September 26 at 1:54 PMLIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancerfinance.yahoo.com - September 20 at 9:28 AMMedia Sentiment Over TimeCompany DescriptionsBriaCell TherapeuticsNASDAQ:BCTXWBriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.Biotech AcquisitionNASDAQ:BIOTW4D pharmaNASDAQ:LBPSWLixte BiotechnologyNASDAQ:LIXTWLixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.